Omidria, Omeros

Integrating new technology into busy ophthalmic ASCAdopting new technologies across multiple practices using a single ambulatory surgery center can be challenging. A systematic approach leverages technology champions, employs consistent communications, and provides administrative support to secure reimbursement.
Cataract surgery 2016: News from the pharmaceutical frontA review of some of the most significant advances in medications for cataract surgery during the past year revealed a mix of the expected with a few surprises.
Drug therapies improving refractive outcomesLines continue to blur as to what constitutes refractive surgery, and likely will continue to blur well into the future. Multiple compounds—phenylephrine and ketorolac 1%/0.3%, (Omidria, Omeros) and the “Dropless” line (Tri-Moxi/Tri-moxi-Vanc, Imprimis Pharmaceuticals)—are designed for use in cataract surgery, but their goal is to improve refractive outcomes. 2015 was the year they started to get some serious attention.
Intracameral combination product brings benefits during, after cataract surgeryThe addition of phenylephrine 1%/ketorolac 0.3% injection to the irrigation bottle maintains pupil dilation and makes patients more comfortable intra- and postoperatively.
News on cataract surgery medications centers on intraocular preparationsIn terms of medication use in cataract surgery, ophthalmologists discussed the continued increasing use of the intracameral route for antibiotic administration to prevent endophthalmitis and the launch of the “Go Dropless” campaign.